We recently reported that a considerable amount of the sodium-D-glucose cotransporter SGLT1 present in Caco-2 cells, a model for human enterocytes, is located in intracellular compartments attached to microtubules (Kipp H, Khoursandi S, Scharlau D, and Kinne RKH. Am J Physiol Cell Physiol 285: C737-C749, 2003). A similar distribution pattern was also observed in enterocytes in thin sections from human jejunum, highlighting the validity of the Caco-2 cell model. Fluorescent surface labeling of live Caco-2 cells revealed that the intracellular compartments containing SGLT1 were accessible by endocytosis. To elucidate the role of endosomal SGLT1 in the regulation of sodium-dependent D-glucose uptake into enterocytes, we compared SGLT1-mediated D-glucose uptake into Caco-2 cells with the subcellular distribution of SGLT1 after challenging the cells with different stimuli. Incubation (90 min) of Caco-2 cells with mastoparan (50 M), a drug that enhances apical endocytosis, shifted a large amount of SGLT1 from the apical membrane to intracellular sites and significantly reduced sodium-dependent ␣-[
endosomes; enterocytes DIETARY D-GLUCOSE IS ABSORBED from the lumen of the small intestine by accumulation of D-glucose into enterocytes. This process is energized by simultaneous "downhill" transport of sodium ions and is mediated by the sodium-D-glucose cotransporter SGLT1. Therefore, the plasma membrane transporter SGLT1 is frequently expected to be located exclusively in the luminal brush-border membrane of enterocytes. However, the distribution of SGLT1 in epithelial cells is more complex. In LLC-PK1 cells, a cell line from the porcine kidney proximal tubule, endogenous SGLT1 was not detected in the brushborder membrane but near the apical plasma membrane (11) . In excised loops from rabbit jejunum, SGLT1 was located in the brush-border membrane and was also proposed to be in intracellular sites (6) .
In Caco-2 cells, a model for human enterocytes, the major amount of SGLT1 was located in intracellular compartments (13) . The intracellular SGLT1 population did not consist of transporters en route from biosynthesis to the plasma membrane, because elimination of transporters from the biosynthesis pathway with cycloheximide did not alter the size or shape of the intracellular SGLT1 pool. Furthermore, intracellular vesicles containing SGLT1 were associated with microtubules. Microtubules are the "railroad tracks" for intracellular vesicular trafficking. Therefore, the intracellular SGLT1 population is very likely to be highly mobile and part of a regulatory mechanism. Actually, there have been several reports of SGLT1-mediated D-glucose uptake regulation likely being related to SGLT1 trafficking. These include regulation of SGLT1-mediated D-glucose uptake by hormones (5), second messengers (17, 25) , protein kinase inhibitors/activators (10, 22, 26) , and extracellular D-glucose levels (19) .
Intracellular trafficking of SGLT1 also is an important issue in the explanation of some pathophysiological states. The autosomal recessive disorder glucose galactose malabsorption syndrome is caused by missense mutations in the SGLT1 gene. Heterologous expression of these mutant SGLT1 genes in Xenopus laevis oocytes led to a complete loss of sodiumdependent D-glucose uptake into oocytes, in contrast to oocytes expressing wild-type SGLT1. Transport deficiency of the mutants was due to a trafficking defect of the SGLT1 protein, which accumulated in intracellular compartments (14) . Therefore, more detailed knowledge of SGLT1 trafficking and regulation in epithelial cells may provide clues for novel therapies for trafficking diseases (1, 2) such as glucose galactose malabsorption syndrome.
In the present study, we demonstrate that intracellular SGLT1 in Caco-2 cells resides in endosomes. These intracellular populations of SGLT1 are also present in absorptive cells of the human jejunum, which highlights the validity of the Caco-2 cell model for the investigation of SGLT1 regulation in human enterocytes. We further explored the role of endosomal SGLT1 in the regulation of D-glucose uptake into cells by comparing SGLT1 distribution with D-glucose uptake into Caco-2 cells after exposure of the cells to various stimuli.
MATERIALS AND METHODS
Materials and cell culture. All chemicals were of the highest purity available and were purchased from Sigma (Deisenhofen, Germany).
Other reagents and antibodies were also obtained from Sigma, unless other sources are indicated. Caco-2 cells were acquired from the Deutsche Sammlung für Mikroorganismen und Zellkulturen (Braunschweig, Germany). Cells were grown in 75-cm 2 flasks (Falcon, Heidelberg, Germany) at 37°C and 5% CO2 in minimal essential medium (Life Technologies) supplemented with 10% fetal calf serum, 1% nonessential amino acids, and 1% glutamine. Every 2 days, the culture medium was renewed. For cell analysis using free-flow electrophoresis, Caco-2 cells (passages [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] were seeded (2 ϫ 10 5 cells/dish) onto 5-cm petriPERM hydrophilic dishes (Vivascience, Hanover, Germany) and grown for 16 -18 days. For D-glucose uptake experiments, Caco-2 cells were seeded (1 ϫ 10 5 cells/well) onto six-well plates (Falcon) and grown for 16 -18 days. Under these growth conditions, Caco-2 cells exhibited high sodium-dependent D-glucose uptake, which is a property of only the fully polarized Caco-2 cell (4).
Tissue sample preparation and immunohistochemistry. Surgically removed samples of normal human jejunum were fixed with 5% formalin and then dehydrated in an ascending ethanol series before being embedded in paraffin. For immunofluorescence light microscopy, labeling was performed on 3-to 5-m-thick paraffin sections according to a previously described incubation protocol (9) .
Endosome labeling, immunocytochemistry, and microscopy. Endosomes of Caco-2 cells, which were grown to confluence on poly-Llysine-coated coverslips, were labeled using a pulse chase protocol. The cell surface was biotinylated with 0.5 mg/ml EZ-Link sulfo-Nhydroxy-succinimidobiotin (Pierce, Rockford, IL) as described previously (23). The biotinylated cells were then chased for 30 min at 37°C to incorporate biotin-labeled proteins into endosomes by fluid-phase endocytosis. Cells were then fixed and used for immunostaining as described previously (13) . Biotin was detected by adding Cy2-streptavidin (Amersham Biosciences, Piscataway, NJ) to the secondary antibody solution. Alternatively, Vybrant CM-DiI cell-labeling solution (Molecular Probes, Eugene, OR) was used to stain the plasma membrane before a chase at 37°C as described above. Fluorescence was observed with a Zeiss Axiophot microscope or with a Noran OZ laser scanning confocal microscopic imaging system connected to a Nikon Eclipse TE200 inverted microscope.
Free-flow electrophoresis and ␣-methyl-D-glucose uptake. The preparation of a cellular organelle fraction from Caco-2 cells, the separation of the cellular organelle fraction by free-flow electrophoresis, the analysis of the fractions obtained by free-flow electrophoresis, and the determination of organelle markers and SGLT1 antigen using a specific antibody were recently described in detail (13) . Sodiumdependent uptake of ␣-[U-
14 C]methyl-D-glucose (300 mCi/mmol; NEN, Boston, MA) into Caco-2 cells was performed as described previously (4, 15) .
RESULTS

SGLT1 distribution in human jejunum.
We recently identified a large intracellular population of SGLT1 in Caco-2 cells (13) . Although Caco-2 cells are a very common cell culture model for human enterocytes, Caco-2 cells were originally derived from a colon carcinoma. The regulation and distribution of SGLT1 in a cancer cell might be different from that in healthy tissue. We therefore investigated the distribution of SGLT1 in samples from human jejunum, which were obtained from the pathology department of a local hospital. Immunostaining with SGLT1-specific antibodies (13) of paraffin sections from human jejunum are shown in Fig. 1 . The major amount of SGLT1 in human jejunum was detected inside absorptive cells, with a more prominent abundance at the apical pole of the cells. Only faint staining of SGLT1 was observed in the brush-border membrane. These observations resemble the results obtained in Caco-2 cells and highlight the validity of this cell culture model for the investigation of SGLT1 regulation in human enterocytes.
Intracellular SGLT1 is located in endosomes. After separation of Caco-2 cell organelles by free-flow electrophoresis, intracellular SGLT1 comigrated with endosomes (13) . However, this does not necessarily prove localization of SGLT1 to endosomes, because intracellular SGLT1 could also be located in organelles with properties comparable to those of endosomes during the separation in an electric field. To test whether intracellular SGLT1 is actually located in endosomes, colocalization of SGLT1 with labeled lipids and labeled membrane proteins internalized from the apical surface of Caco-2 cells was investigated (Fig. 2) . Intracellular structures containing SGLT1 match in size and shape with parts of the compartments labeled by internalized fluorescent lipids and membrane proteins, suggesting that the intracellular SGLT1 population is formed by endocytosis. However, not all endosomes labeled by internalized fluorescent lipids and membrane proteins also contain SGLT1, indicating that SGLT1 is found only in a subpopulation of the endosomes present in Caco-2 cells.
The existence of a large network of endosomes containing SGLT1 raises questions about its physiological role. In an earlier study (13) , we reported that intracellular compartments containing SGLT1 are attached to microtubules. We therefore assume that intracellular SGLT1 is highly mobile and part of a mechanism by which SGLT1 abundance at the apical cell surface is regulated in response to an altered physiological demand for sodium-dependent D-glucose uptake into enterocytes. To test this hypothesis, we studied the effect of mastoparan, a drug that enhances apical endocytosis in some cells (8) , and the effect of altered extracellular D-glucose levels on sodium-dependent ␣-methyl-D-glucose uptake and SGLT1 distribution in Caco-2 cells.
Effect of mastoparan. Mastoparan is a tetradecapeptide and a constituent of wasp venom. It is known to activate heterotrimeric G proteins and to enhance apical endocytosis in MadinDarby canine kidney cells (8) . To test whether mastoparan also enhances apical endocytosis in Caco-2 cells, fluid-phase endocytosis of horseradish peroxidase into Caco-2 cells was measured in the absence and presence of mastoparan (Fig. 3) . Mastoparan (50 M) in the incubation medium significantly (Ͼ3-fold) enhanced endocytosis of horseradish peroxidase in Caco-2 cells as well.
Mastoparan treatment had a significant inhibitory effect on sodium-dependent ␣-methyl-D-glucose uptake into Caco-2 Fig. 2 . SGLT1 is located in endosomes. 0 min: plasma membrane of Caco-2 cells grown to confluence on poly-L-lysine-coated coverslips was labeled with the fluorescent lipid DiI or biotin (red) at 0°C. After fixation of the cells, SGLT1 (green) was stained with a specific antibody. 30 min: in another preparation, DiI or biotin was allowed to be endocytosed from the plasma membrane by incubation of the cells for 30 min at 37°C. The cells were then fixed, and SGLT1 was stained with a specific antibody. DiI fluorescent lipid label is shown in red, and SGLT1 is shown in green. Experiments with DiI were observed using epiflourescence microscopy, and experiments with biotin were observed using confocal microscopy. Incubation with only the secondary antibodies revealed no significant fluorescence (data not shown). Scale bars, 15 m. cells, which is a measure of transport-active SGLT1 present at the apical cell surface. Incubation of Caco-2 cells with various concentrations of mastoparan for 90 min (Fig. 4) significantly decreased ␣-methyl-D-glucose uptake into cells in a concentration-dependent manner. To investigate whether this effect was due to a reduced amount of SGLT1 present at the apical cell surface, we determined the distribution of SGLT1 in control cells and in cells incubated with 50 M mastoparan for 90 min by free-flow electrophoresis (13) (Fig. 5) . Incubation of Caco-2 cells with mastoparan significantly diminished the amount of SGLT1 present in the apical membrane in parallel with an increase in the intracellular amount of SGLT1 (Fig.  5A) . Interestingly, after treatment of Caco-2 cells with mastoparan, the amount of SGLT1 in early as well as late endosomal fractions increased, with the latter suggesting that the rate of lysosomal SGLT1 degradation may increase in response to a forced enhanced endocytosis rate. A comparison of the ratios between intracellular and apical SGLT1 (Fig. 5B) revealed that in control experiments, there is about twofold more SGLT1 in intracellular compartments than at the cell surface. This ratio increased in mastoparan-treated cells to a fourfold greater intracellular amount of SGLT1. A shift in the subcellular SGLT1 distribution was also detected using immunostaining of endogenous SGLT1 in Caco-2 cells treated with mastoparan (50 M, 90 min) (Fig. 6) . Compared with the distribution in control cells, in mastoparan-treated cells, the compartments containing SGLT1 were condensed to bigger structures that were arranged around the nucleus.
These data demonstrate that the cellular pool of SGLT1 can be shifted from the plasma membrane to intracellular compartments and that this shift alters the cell's capability to conduct sodium-dependent D-glucose uptake. However, the regulation of sodium-dependent D-glucose uptake by mastoparan is pharmacologically induced and therefore is not necessarily relevant to the regulation of SGLT1-mediated D-glucose uptake into cells under physiological conditions. To study the effect of a potential, more physiological regulator, we investigated the effect of varying extracellular D-glucose levels on SGLT1-mediated ␣-methyl-D-glucose uptake into Caco-2 cells.
Effect of altered extracellular D-glucose levels. The D-glucose level in the lumen of the small intestine varies depending on the nutritional state of the individual, and the lower limit is probably 0 mM D-glucose after a fasting period. After a meal, Fig. 4 . Mastoparan inhibits sodium-dependent ␣-methyl-D-glucose uptake into Caco-2 cells. Caco-2 cells grown to polarity in 6-well plates were incubated with various concentrations of mastoparan for 90 min at 37°C. Sodiumdependent uptake of ␣-methyl-D-glucose over 10 min was then determined. Sodium-dependent uptake of ␣-methyl-D-glucose was also determined in the presence of 0.5 mM phlorizin, a specific inhibitor of SGLT1. Values are means Ϯ SD; n ϭ 3. the action of membrane-bound hydrolytic enzymes, located in the microvilli of enterocytes, on sugars such as maltose, sucrose, and ␣-limit dextrins results in a high local concentration of D-glucose. Luminal D-glucose concentration in the upper jejunum is estimated to exceed 50 mM and probably is much higher in the unstirred layer close to the site of terminal carbohydrate digestion (7) . Actually, these maximal local concentrations were calculated to be as high as 200 -300 mM (18) . Therefore, extracellular D-glucose concentrations of 0 -100 mM were investigated in the present study.
Caco-2 cells were incubated with D-glucose-free medium or with medium containing 50 or 100 mM D-glucose for 1 h. The incubation media were adjusted with D-mannitol to maintain osmolarity. The cells were then washed, and the sodiumdependent uptake of [
14 C]-␣-methyl-D-glucose was measured for 10 min (Fig. 7) . In cells preincubated with 50 or 100 mM D-glucose, sodium-dependent uptake of ␣-methyl-D-glucose was significantly inhibited (by 20 and 45%, respectively) compared with preincubation in D-glucose-free medium. The same experiment was also performed in the presence of 50 M nocodazole, a drug that depolymerizes microtubules. When microtubules were depolymerized, sodium-dependent ␣-methyl-D-glucose uptake was lower in all instances, but more interestingly, no inhibitory effect due to prior incubation with high D-glucose medium was observed. These data suggest that the regulation of sodium-dependent ␣-methyl-D-glucose uptake by extracellular D-glucose levels requires an intact microtubule network.
Investigation of the subcellular SGLT1 distribution by freeflow electrophoresis after exposure of Caco-2 cells to Dglucose-free or high D-glucose medium revealed no significant changes (Fig. 8A) . In all instances, the ratio between intracellular and apical SGLT1 was ϳ2:1 (Fig. 8B) .
DISCUSSION
Several studies have demonstrated regulation of SGLT1-mediated sodium-dependent D-glucose absorption, which includes transcriptional long-term regulation caused by changes in dietary carbohydrate levels (16) . However, there also have been reports of acute short-term effects on sodium-dependent D-glucose uptake into cells. SGLT1-mediated D-glucose uptake into cells was rapidly altered by prior treatment with forskolin (25) , cAMP or the cAMP-raising agent cholera toxin (17) , the peptide hormone glucagon-like peptide 2 (5), epidermal growth factor (6) , and high extracellular D-glucose (19) . In several of these examples, a shift of SGLT1 between the plasma membrane and other cellular locations has been postulated or directly demonstrated.
Comparable results were obtained in the present study. Short-term (90 min) exposure of Caco-2 cells to mastoparan, a drug known to enhance apical endocytosis, acutely redistributed SGLT1 from the plasma membrane to intracellular sites paralleled by a significant attenuation of sodium-dependent D-glucose uptake into the cells. The general scheme underlying Fig. 6 . Mastoparan changes intracellular SGLT1 distribution in Caco-2 cells. Caco-2 cells were grown to confluence on poly-Llysine-coated coverslips and incubated for 90 min with medium containing 50 M mastoparan at 37°C. The cells were then fixed and permeabilized. SGLT1 was labeled with a specific antibody (red). Nuclei were stained with DAPI (blue). Control cells were not treated with mastoparan. The fluorescence of the labels was observed using epifluorescence microscopy. Incubation with only the secondary antibody revealed no significant fluorescence (data not shown). Scale bars, 15 m. the action of mastoparan and probably many other agents described in the literature is very likely a drug-initiated general change in the sorting of transporters, which leads to decreased or enhanced endocytosis of SGLT1, thereby increasing or decreasing the number of transporters at the cell surface, which ultimately leads to increased or decreased sodium-dependent D-glucose uptake into the cell. However, regulation of SGLT1-mediated D-glucose uptake by extracellular D-glucose levels differs from this scheme. Low extracellular D-glucose increases and high extracellular D-glucose downregulates SGLT1-mediated D-glucose uptake into Caco-2 cells. This occurs without a change in the cellular steady-state distribution of SGLT1.
It is surprising at first glance that SGLT1-mediated Dglucose uptake decreases when Caco-2 cells are challenged with high extracellular D-glucose. In addition, enhanced sodium-dependent D-glucose uptake into brush-border membrane vesicles prepared from rat small intestine that was exposed to high D-glucose was reported previously (19) . These conflicting data may be explained by the different methodological approaches used. Another explanation may be the diverse pathways engaged in intestinal D-glucose absorption. Besides cellular uptake mediated by SGLT1, a paracellular pathway for D-glucose (18) and the involvement of apical GLUT2, a transporter allowing facilitated diffusion of D-glucose, also have been postulated. High luminal D-glucose has been reported to induce recruitment of GLUT2 to the brush-border membrane, and the GLUT2-mediated diffusion of D-glucose across the brush-border membrane in that situation represents the major route of D-glucose uptake into enterocytes (12) . To circumvent interference from this transporter, we used ␣-methyl-D-glucose exclusively to measure SGLT1-mediated substrate uptake into Caco-2 cells. ␣-Methyl-D-glucose is a specific substrate for SGLT1, but not for GLUT2 (3). It is therefore possible that total D-glucose uptake via multiple pathways into Caco-2 cells increases after exposure to high extracellular D-glucose, even if the SGLT1-mediated pathway decreases. A decrease in energy requiring transport may be one physiological reason for the downregulation of SGLT1 in enterocytes under high luminal D-glucose conditions. Another reason is probably the prevention of a multiplication of the osmotic challenge to enterocytes, because via SGLT1, with every D-glucose molecule, two sodium ions are transported into the cell as well.
How can regulation of D-glucose uptake without a change in the cellular SGLT1 steady-state distribution be explained? Toward this end, two observations are of significance. The first important observation is that regulation of SGLT1-mediated D-glucose uptake without cellular redistribution of transporters works at all! This is possible only if SGLT1 molecules themselves are regulated in their transport activity. The second important observation is the association of SGLT1-containing endosomes with microtubules, which we found in an earlier study (13) . Microtubules are the railroad tracks for vesicular trafficking, which suggests mobility of the cellular SGLT1 pool, and the induction of SGLT1 trafficking with mastoparan in the present study demonstrates that the cellular SGLT1 pool is indeed mobile. Inhibition of this mobility by microtubule depolymerization with nocodazole inhibited the regulatory response to altered extracellular D-glucose levels. Thus SGLT1 activation/inactivation as well as trafficking of transporters seems to be part of the mechanism that regulates SGLT1-mediated D-glucose uptake in response to extracellular Dglucose levels. Taking these properties into account, we assume a mechanism that includes membrane protein cycling and activation/inactivation steps similar to those involved in the regulation of cell surface receptors such as G protein-coupled receptors (21) , cytokine receptors (20) , and the epidermal growth factor receptor (24) . In this hypothetical scheme, SGLT1 in the apical membrane is inactivated after a certain time with regard to D-glucose transport capability and is then endocytosed. Endosomal SGLT1 in turn is eventually activated and then returned to the plasma membrane. Sodium-dependent D-glucose uptake into the cell could then be regulated without altering the cellular steady-state distribution of SGLT1 by changing the velocity of this SGLT1 activation/inactivation cycle, which ultimately determines the amount of transportactive SGLT1 in the apical membrane.
Our present study suggests that in addition to the obvious mode of SGLT1 regulation by shifting transporters between locations, there is another regulatory mechanism that includes SGLT1 trafficking and activation/inactivation steps of the transporter. A challenge for the future is to actually prove the coexistence of cellular pools of transport-active and -inactive SGLT1 and to discriminate between them. This project is presently being pursued in our laboratory.
